Spruce Biosciences, Inc.
SPRB
$0.0878
-$0.042-32.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.68% | 19.72% | 10.49% | 0.97% | -3.77% |
| Total Depreciation and Amortization | -34.29% | -32.05% | -28.57% | -8.33% | -5.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.69% | 86.22% | 91.72% | 66.26% | 28.17% |
| Change in Net Operating Assets | -182.76% | -206.47% | -180.62% | 110.19% | 814.84% |
| Cash from Operations | -68.19% | -37.55% | -64.52% | 12.50% | 20.17% |
| Capital Expenditure | -- | 100.00% | -250.00% | 12.50% | 12.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -84.77% | -22.75% | 8.70% | 135.38% |
| Cash from Investing | -- | -84.77% | -22.77% | 8.70% | 135.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -33.39% | -100.00% | -300.49% | -- |
| Issuance of Common Stock | -99.54% | -99.44% | -99.44% | -99.33% | 68,866.67% |
| Repurchase of Common Stock | 20.90% | -144.68% | -71.64% | -360.32% | -677.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 97.82% | -875.27% |
| Cash from Financing | -103.30% | -103.11% | -103.10% | -103.21% | 20,490.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -180.38% | -150.34% | -155.50% | -85.65% | 492.95% |